报价延迟最少15分钟:2026/04/22 13:15 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.535 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.57/-0.25
|
|
企业价值
230.73M
|
| 资产负债 |
|
每股账面净值
1.84
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
18.67M
|
|
每股收益
0.46
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. |
